Switzerland, AI and Liquid Biopsies

Faces of Digital Health

AI and predictive modeling to understand an individual’s immune system function and predict treatment response are still in very early stages. We dream about precision medicine and getting every answer we can for ourselves when we get sick. However, if we look at genomics, only about 20 percent of human coding genes are well-studied. The remaining 80 percent (about 16,000 genes, along with the proteins they make) are largely a mystery.

In this episode, you will hear more about the field of immuno-oncology, understand the correlation between tumor development and immune system response, and trends in cancer detection and prevention, especially liquid biopsies - tests for detecting tumors in blood samples.

Speaker: Brian Hashemi - Executive Chairman and CEO of Novigenix - a Swiss-based biotech company using AI and RNA sequence analysis to capture the cancer immunity cycle during the multi-stage disease progression and response to therapy.

www.facesofdigitalhealth.com

https://fodh.substack.com/

Show notes:

[00:02:00] The use of AI and RNA sequence analysis in capturing the cancer immunity cycle and disease progression

[00:04:00] Biotech in Switzerland

[00:06:00] The impact of Swiss biotech capabilities on global healthcare and the specific advancements made by Swiss companies in the field.

[00:08:00] Predictions and hopes for the future of healthcare technology, especially in the realms of cancer detection and treatment.

[00:10:00] Challenges and opportunities in biotech, and the role of AI in advancing healthcare.

[00:12:00] Challenges in Colorectal Cancer Screening

[00:14:00] The Impact of Liquid Biopsy on Clinical Trials and Drug Development

[00:16:00] Market Adoption and Patient Accessibility to Liquid Biopsy Tests

[00:18:00] The Future of Liquid Biopsy and Precision Medicine

[00:20:00] Real-world Application and Impact of Novel Biomarkers

[00:22:00] Expanding the Reach of Novel Diagnostics Beyond Switzerland

[00:24:00] Partnerships and Collaborations to Accelerate Adoption